Sg3 Management, LLC Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $342,300 - $529,800	-15,000 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $380,250 - $479,400	15,000 Added 100.0%	30,000 $946,000
Q3 2022 May 15, 2023	SELL	$25.5 - $41.42 $382,500 - $621,300	-15,000 Reduced 50.0%	15,000 $423,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $382,500 - $621,300	15,000 New	15,000 $424,000
Q1 2022 May 16, 2022	BUY	$23.5 - $35.38 $481,750 - $725,290	20,500 New	20,500 $718,000
Q4 2021 Feb 15, 2022	SELL	$29.21 - $44.64 $292,100 - $446,400	-10,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.26 - $38.85 $212,600 - $388,500	10,000 New	10,000 $295,000

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.